Physician profile
Michael Santoro
NPI 1396722435
$9,968.33
in general payments reported to CMS, 2019-2025
34 companies · $3,179 in 2025
The $3,179 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $716 · 2020: $247 · 2021: $125 · 2022: $1,253 · 2023: $1,827 · 2024: $2,621 · 2025: $3,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,627.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,633.08 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $1,324.78 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $896.15 | 2019-2025 | Entyvio, Eohilia, Vpriv |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $698.66 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Pfizer INC. | $647.56 | 2019-2025 | |
| Genzyme Corporation | $533.93 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $289.86 | 2023-2025 | Voquezna |
| Lilly USA, LLC | $222.19 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $183.49 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $174.51 | 2019-2023 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $168.35 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $134.08 | 2024-2025 | Ibsrela |
| Daiichi Sankyo INC. | $102.05 | 2020-2022 | |
| Aimmune Therapeutics, INC. | $95.36 | 2025 | Zenpep |
| Capsovision, INC. | $88.91 | 2025 | Capsocam Plus |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $80.96 | 2022-2025 | Sutab, Suflave |
| Vivus LLC | $79.25 | 2019-2025 | Pancreaze, Qsymia |
| Gilead Sciences, INC. | $72.54 | 2019-2025 | |
| Celgene Corporation | $61.16 | 2023-2024 | Zeposia |
| Redhill Biopharma INC. | $60.57 | 2022-2023 | Talicia, Movantik, Aemcolo |
| Ferring Pharmaceuticals INC. | $53.24 | 2022-2024 | Clenpiq, Rebyota |
| Medtronic, INC. | $51.53 | 2022-2024 | Nexpowder |
| Alfasigma USA, INC. | $43.91 | 2022 | |
| Celltrion USA INC. | $36.22 | 2024-2025 | Vegzelma, Zymfentra |
| Fresenius Kabi USA, LLC | $32.87 | 2023 | |
| Shionogi INC | $31.60 | 2019 | |
| Merck Sharp & Dohme LLC | $31.10 | 2019-2020 | |
| Qol Medical, LLC | $28.14 | 2025 | Sucraid |
| Nestle Healthcare Nutrition INC. | $25.55 | 2022 | |
| Lucid Diagnostics INC. | $24.43 | 2022 | |
| Albireo Pharma, INC. | $17.89 | 2024 | Iqirvo |
| Exact Sciences Corporation | $17.21 | 2023 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $14.68 | 2022 | |
| Allergan, INC. | $12.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Santoro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.